리포트 아카이브
전체 리서치
52페이지 중 15페이지 · 리포트 1235건
44/100
KINGSEMI: A Scarce Domestic Track Asset, Priced Well Ahead of the Evidence
KINGSEMI is a specialized Chinese semiconductor-equipment maker in front-end coat/develop tracks and single-wafer wet tools, now controlled by NAURA. 2025 revenue grew 11% to CNY 1.95 billion, but attributable profit fell 65% to CNY 71.7 million, and a one-month 79% surge lifted the market cap to CNY 88.5 billion, about 45 times sales. Rating Avoid: a genuinely scarce front-end track franchise, but at CNY 439 the price already assumes a mature cleaning-and-platform business the operating evidence does not yet support.
41/100
Mitsubishi Electric: A Conglomerate in Transition, Fully Priced
Mitsubishi Electric is a diversified Japanese electrical group earning from factory automation, infrastructure, HVAC and building systems, semiconductors and defense, with FY2026 revenue of ¥5.9 trillion. All five segments grew profit in FY2026 and management is pushing ROIC-based reform, ¥280 billion of cross-shareholding sales and a richer service mix, yet free cash flow of ¥231.5 billion still trails net profit of ¥407.7 billion while the stock has rerated to around 30x trailing earnings. Rating Hold: business quality and capital discipline are genuinely better, but at ¥5,858 the price already discounts much of the reform before cash conversion catches up, leaving little margin of safety.
51/100
Meituan: A High-Quality Franchise With Temporarily Broken Earnings
Meituan is China's largest local-services platform, monetizing food delivery, in-store and hotel services, and instant retail, with 2025 revenue of RMB364.9 billion. A subsidy war with Alibaba and JD flipped Core Local Commerce from RMB52.4 billion of 2024 operating profit into a loss and pushed the group to a RMB23.4 billion net loss in 2025, even as platform GTV and transaction volume kept growing. Rating Hold: the franchise stays high-quality and the balance sheet strong, but at HK$68.50 the shares lack a clear margin-of-safety cushion until Core Local Commerce proves post-war profitability can stick.
U.S. Market Close Daily | 2026-06-30
U.S. stocks closed higher in high-level consolidation as AI-chip leadership and improving late breadth offset higher Treasury yields.
52/100
57Buffett
Anji Microelectronics: A High-Quality Compounder, but a Better Company Than Stock
Anji Microelectronics is China's leading CMP-slurry maker, supplying semiconductor polishing slurries and a widening platform of formulated wet electronic chemicals, with 2025 revenue of CNY 2.50bn (up 36%) and a disclosed global CMP-slurry share that climbed from about 7% in 2022 to 13% in 2025. The usage story is genuine: attributable net profit grew 47% to CNY 784m and functional wet chemicals surged 64%, yet after a roughly 161% one-year run the stock trades near CNY 305, about 88 times 2025 earnings, a price that already capitalizes years of flawless execution. Rating Watch: a real hard-tech compounder, but currently a better company than stock, with a serious re-underwriting zone only back at CNY 190-230.
U.S. Market Close Daily | 2026-06-29
U.S. stocks rebounded sharply from a five-day slide as AI and semiconductor leadership returned, but narrow breadth kept the tape in an oversold-rebound state.
42/100
Schaeffler: More Interesting Than Its Multiple, but Not Yet Safer Than It Implies
Schaeffler is a German motion-technology supplier (bearings, automotive aftermarket, and electrification systems), reshaped into a four-division group after the 2024 Vitesco merger, with 2025 revenue of EUR 23.5 billion. The legacy bearings and aftermarket businesses are better than the stock's distressed-supplier multiple implies, but E-Mobility still ran a -16% adjusted EBIT margin in 2025 and EUR 4.9 billion of net debt keeps the group below investment grade, so the cheap multiple reflects real transition risk rather than hidden value. Rating Watch: buy only at a larger discount (ideal entry EUR 6.2-6.9) or after clearer proof that E-Mobility losses and leverage are turning.
42/100
Beijing Jingyi: A Genuine Semiconductor Subsystem Business at an Increasingly Demanding Price
43/100
35Buffett
TechnipFMC: A Higher-Quality Subsea Franchise Now Priced for Continued Delivery
TechnipFMC is a focused subsea production-systems and SURF contractor whose earnings are anchored by a record offshore order book. A 16.57 billion USD backlog, free cash flow that doubled to 1.45 billion USD, and a swing to net cash have re-rated it from a post-merger cleanup story into a cyclical-quality franchise. Rating Hold: a genuinely better subsea business, but at 64.44 USD the price already discounts most of the backlog and cash-conversion improvement, leaving a thin margin of safety.
50/100
71Buffett
UCB SA: A Specialty-Biopharma Growth Platform That Has Already Re-Rated
UCB is a Belgian specialty biopharma in immunology and neurology, and BIMZELX is now its largest product at €2.227 billion of 2025 net sales. FY2025 revenue rose 26% to €7.741 billion, adjusted EBITDA jumped to €2.636 billion, and the balance sheet swung from €1.454 billion of net debt to roughly net cash; yet at €258.50, about 24x forward earnings, the price already embeds much of the BIMZELX and portfolio ramp. Rating Hold: a genuinely stronger company at a price that leaves essentially no margin of safety for fresh capital.
38/100
21Buffett
Hecla Mining: A Cleaner, Debt-Free Silver Major Still Priced Without a Margin of Safety
Hecla Mining is North America's largest silver producer, now a debt-free, three-mine platform (Greens Creek, Lucky Friday, Keno Hill) that turned the 2025 cyclical upswing into 1.423 billion USD of sales and 310.2 million USD of free cash flow. Asset quality and the balance sheet have genuinely improved, but at 15.54 USD the stock already discounts most of that, and the upside is driven by silver-price beta rather than durable compounding. Rating Hold: a cleaner, better-run silver major worth holding, with no margin of safety for new money until it falls toward the 10-11 USD ideal-buy zone.
42/100
Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent
Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
36/100
Panasonic Holdings: Better Business, Priced Ahead of Proof
Panasonic Holdings is a diversified Japanese electronics group whose earnings base is still mature B2B and appliance operations, while batteries and AI-infrastructure products drive the growth narrative. FY2026 sales were ¥8.05 trillion across six segments, but ROE fell to 3.8% on ¥174.5 billion of restructuring charges, and the shares are up about 68% in 2026 on an AI-infrastructure rerating that capitalizes one hot battery-and-data-center engine across the whole group. Rating Hold: the business mix is genuinely improving, but at ¥4,540 the price already discounts most of the battery, AI-infrastructure, and restructuring upside, leaving no margin of safety against a conservative fair value near ¥2,400-¥2,690.
47/100
Symrise: A High-Quality Compounder Now Priced for Delivery, Not Discovery
Symrise is a scaled, oligopolistic flavors-and-fragrances and nutrition platform that gets paid for being embedded in customers' everyday products, with 2025 sales of €4.93 billion, a 21.9% adjusted EBITDA margin and record €780 million of business free cash flow. The 2026 question is delivery, not discovery: organic growth has cooled from 8.7% in 2024 to low single digits in 2025 and slightly negative in Q1 2026, yet cash conversion, leverage and margin quality all improved, so the franchise is intact while the near-term growth premium is not obviously earned. Rating Hold: a high-quality compounder whose €88.16 price already reflects most of the self-help and recovery, with a more comfortable margin of safety only in the high-€50s to mid-€60s.
47/100
JD.com: A Stronger Retail Core Discounted for the Cost of Transition
JD.com is China's largest self-operated online retailer, built on a supply-chain-first model spanning first-party retail, marketplace services, logistics, health and industrial procurement. Its retail core is strengthening, with JD Retail operating margin up to 5.6% in Q1 2026 and net service revenue growing 20.6% against just 1.0% product growth, yet group profit and cash conversion are obscured by heavy food-delivery and overseas investment, while listed-subsidiary stakes worth about US$17.7 billion anchor a sum-of-the-parts case. Rating Cautious Buy: the market discounts the cost of transition more than it credits a stronger retail core, large buybacks and visible listed stakes.
46/100
FUJIFILM Holdings: A Proven Reinventor Now Tested on Returns, Not Survival
FUJIFILM Holdings is a diversified Japanese technology group earning ¥3.36 trillion of FY2026 revenue across healthcare and Bio CDMO, semiconductor materials, imaging (instax) and office systems. Electronics and Imaging already supply about ¥260.9 billion, roughly three-quarters of segment operating profit, yet Healthcare ROIC is only 1.6%, FY2026 free cash flow is negative amid a capex bulge, and owner earnings near 23 times sit well above the 15.7 times headline P/E. Rating Hold: the transformation from film survivor to multi-engine compounder is real, but healthcare returns and owner earnings still lag the price, leaving no margin of safety until below ¥2,650.
49/100
ACM Research: A Credible China Semicap Franchise, a Demanding Holdco Structure
ACM Research is a Nasdaq-listed holding company whose value is dominated by its roughly 73.6%-owned, Shanghai-listed subsidiary ACM Shanghai, built on a single-wafer wet-cleaning franchise now broadening into plating, furnace, track and PECVD. The parent trades at a steep discount to the quoted value of that stake, yet the A-share quote is already rich, four customers make up 52.2% of 2025 revenue, and first-quarter 2026 free cash flow was negative 52.1 million USD. Rating Hold: strong China semicap execution is real, but at 104.50 USD the price offers too little protection against cash-conversion, policy and holdco-structure risk.
49/100
85Buffett
Bentley Systems: Durable Infrastructure Compounder, Thin Margin of Safety
Bentley Systems is a specialized infrastructure-engineering software vendor whose economic engine is a recurring estate embedded in civil, utility, and owner-operator workflows, with $1.495 billion ARR, 93% recurring revenue, 99% account retention, and 109% net retention. Full-year 2025 revenue rose 11.0% to $1.502 billion and free cash flow reached $520.2 million, yet a dual-class structure leaves the Bentley Control Group with about 62.8% of voting power and the $30 price sits roughly at conservative fair value. Rating Hold: a high-quality, sticky compounder whose cash conversion the headline P/E understates, but founder control and a thin margin of safety make a fresh buy more attractive below $25.
44/100
Black Sesame International: Credible Challenger, Unproven Cash Conversion
Black Sesame is a fabless designer of automotive compute SoCs, selling ADAS chips and bundled solutions; 2025 revenue rose 73% to RMB822 million, yet it stays deeply loss-making with R&D near 1.7x sales. It has crossed the technical-credibility threshold (A1000 shipping in Geely, BYD and FAW models) but not the cash-conversion one, leaning on repeated 2025-2026 equity raises. Rating Hold: real commercialization exists, but recurring dilution and negative owner earnings cap valuation support, with a true margin of safety only below about HK$6.
57/100
88Buffett
Belimo Holding: AI 냉각의 긴 활주로를 이미 가격에 반영한 프리미엄 HVAC 컴파운더
Belimo는 난방, 냉방, 환기를 조절하는 액추에이터, 제어 밸브, 센서, 계량기 등 HVAC 필드 디바이스 분야의 스위스 순수 플레이 리더로, 시공·개보수 채널을 통해 매출의 약 60%, OEM 채널을 통해 약 40%를 판매하며, 자사가 공급하는 통합 빌딩 자동화 대기업들과는 경쟁하지 않는다. 2025년 매출은 현지 통화 기준 23.3% 증가한 CHF 11.208억을 기록했으며, EBIT 마진 20.8%, ROIC 27.8%를 기록했다. 매출의 약 17%를 차지하는 AI 데이터센터 액체 냉각이 내구성 있는 에너지 효율 개보수 프랜차이즈 위에 두 번째 성장 엔진이 되었지만, 후행 이익의 약 61배에 거래되는 주가는 자체 과거 범위의 상단 부근에 있다. 등급은 관찰: 진정으로 뛰어난 니치 컴파운더이지만, 주가는 이미 탁월함과 긴 AI 냉각 활주로를 모두 반영하고 있어, 더 매력적인 진입점은 대략 CHF 480 아래에서만 나타난다.
53/100
80Buffett
Sika AG：순환적 에어포켓 속 고품질 컴파운더
Sika는 건설용 화학제품(혼화제, 방수재, 실란트, 지붕재, 산업용 접착제) 분야의 세계적 리더로, 100개국 이상 400개 이상의 공장을 통해 현지에 맞춘 시스템을 판매하며, Parex와 MBCC 같은 볼트온 M&A를 사업 모델에 편입시켰다. 2025년 매출은 스위스 프랑 강세와 건설 경기 둔화로 4.8% 감소한 112.0억 스위스프랑을 기록했지만, 현지 통화 기준 성장은 플러스를 유지했고 소재 마진은 54.9%로 상승했으며 MBCC 시너지는 1.82억 스위스프랑에 달했다. 등급은 보유: 일류 시리얼 인수자형 컴파운더가 순환적 에어포켓에 갇혀 있지만, 직전 이익의 약 26배라는 밸류에이션은 오가닉 성장이 회복되기도 전에 마진 회복분의 상당 부분을 이미 반영하고 있다.
51/100
81Buffett
NARI Technology: Grid-Control Franchise, Quality Already Priced
NARI is the dominant listed proxy for China's grid-control layer: dispatch software, relay protection, UHV control and energy-management systems built around State Grid. 2025 revenue reached RMB 66.23bn with operating cash flow of RMB 12.77bn, yet revenue is outgrowing profit as the mix shifts toward lower-margin storage and outside-grid work. Rating Hold: a high-quality policy-cycle compounder whose roughly 22x trailing valuation leaves little margin of safety against further mix dilution.
48/100
AVIC Jonhon Optronic: Defense-Grade Interconnect Leader, Recovery Already Priced
AVIC Jonhon is a Chinese high-reliability interconnect maker whose defense-grade connector core still carries the business (connectors are 98.5% of revenue) while EVs, data centers and optics become the larger growth engine. 2025 revenue edged up 3.4% to RMB 21.39 billion but attributable profit fell 35.6% to about RMB 2.16 billion as defense demand softened and gold, copper and silver costs surged, and at RMB 42.69 the stock already trades on a mid-40s trailing multiple that discounts a recovery while cash conversion stays weak. Rating Hold: the franchise is intact and a rebound is plausible, but today's price pre-spends most of it with no margin of safety.